NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 82 resultados LastUpdate Última actualización 22/02/2020 [15:05:00] pdf PDF

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days

Página1 de 4 nextPage   por página


HYBRIDOMA CELL LINE SECRETING MONOCLONAL ANTIBODY AGAINST THIAMETHOXAM AND USE THEREOF

NºPublicación: WO2020034547A1 20/02/2020

Solicitante:

UNIV JIANGNAN [CN]

CN_108998422_A

Resumen de: WO2020034547A1

A hybridoma cell line secreting a monoclonal antibody against thiamethoxam, wherein the deposit number of the hybridoma cell line is: CGMCC No.14699. The cell line can be obtained by the steps of: immunizing BALB/c mice with a complete Freund's adjuvant for the first time, with an incomplete Freund's adjuvant for three booster immunizations, and with the thiamethoxam complete antigen without an adjuvant for one impact immunization to immunize the BALB/c mice; fusing the immunized mouse spleen cells with high titer and low IC50 with mouse myeloma cells by a PEG method, and subjecting same to the indirect competitive ELISA screening and three subclonings. The monoclonal antibody secreted by the cell line can be used for the detection of thiamethoxam residues in food.

traducir

ANTICANCER COMPOSITIONS AND METHODS FOR MAKING AND USING THEM

NºPublicación: US2020054666A1 20/02/2020

Solicitante:

UNIV CALIFORNIA [US]

Resumen de: US2020054666A1

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating or ameliorating a cancer by inhibiting expression or activity of Mouse Double Minute 2 homolog (MDM2), an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or an ADAR1p150 protein, message (mRNA) or gene, e.g., by increasing the presence of in a cell or adding to a cell a molecule inhibitory to MDM2, APOBEC3G and/or ADAR1p150 expression, such as an miRNA that binds to MDM2, APOBEC3G and/or ADAR1p150 transcripts, or any molecule that can inhibit or destabilize the transcripts, resulting in decreased MDM2, APOBEC3G and/or ADAR1p150 expression, to treat a cancer such as leukemia, e.g., by inhibiting the propagation of a cancer cell, a leukemia cell, a leukemia stem cell (LSC) or a pre-leukemia cell stem cell (pre-LSC).

traducir

METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER

NºPublicación: US2020054640A1 20/02/2020

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
ST JUDE CHILDRENS RES HOSPITAL [US]

US_2017173021_A1

Resumen de: US2020054640A1

A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.

traducir

COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES

NºPublicación: US2020054639A1 20/02/2020

Solicitante:

UNIV OREGON HEALTH & SCIENCE [US]

WO_2018081830_PA

Resumen de: US2020054639A1

Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.

traducir

THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS

NºPublicación: US2020054596A1 20/02/2020

Solicitante:

LOWE HENRY [JM]
TOYANG NGEH J [US]

US_2018353462_A1

Resumen de: US2020054596A1

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.

traducir

Use of Non-Peptidic NK1 Receptor Antagonists for the Production of Apoptosis in Tumour Cells

NºPublicación: US2020054620A1 20/02/2020

Solicitante:

NK 1 IP LTD [GB]

US_2018117027_A1

Resumen de: US2020054620A1

The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.

traducir

Compositions and Methods for Treating Patients Suffering from Glioma or Leukemia

NºPublicación: US2020054591A1 20/02/2020

Solicitante:

UNIV CINCINNATI [US]

WO_2018085486_PA

Resumen de: US2020054591A1

Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering from glioma or leukemia with a MYC-signaling inhibitor followed by or cotemporaneous with treatment with R-2HG, and optionally other chemotherapeutic agents.

traducir

DETECTION OF MELANOMA AND LYMPHOMA BY ATR-FTIR SPECTROSCOPY

NºPublicación: US2020056991A1 20/02/2020

Solicitante:

GEORGIA STATE UNIV RESEARCH FOUNDATION INC [US]

Resumen de: US2020056991A1

The present disclosure relates to methods for the detection of melanoma and non-Hodgkin's lymphoma using attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy. Further disclosed are methods for treating melanoma and non-Hodgkin's lymphoma, based on differences in infrared absorbance.

traducir

METHOD OF PRODUCING NAIVE PLURIPOTENT STEM CELLS

NºPublicación: US2020056150A1 20/02/2020

Solicitante:

FENG JIAN [US]

WO_2018085419_PA

Resumen de: US2020056150A1

Provided herein are compositions and methods for generation of naive human pluripotent stem cells. The method comprises incubation of iPSCs under 5% O2 in a medium comprising 5% glucose, an MEK inhibitor, a GSK3β inhibitor, human leukemia inhibitory factor (LIF), human insulin and Torin 1. The method does not need any other inhibitors or transgene expression. The naive human pluripotent cells can be used to generate a large amount of mature human cells from all three germ layers in host non-human animals.

traducir

CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR

NºPublicación: US2020055948A1 20/02/2020

Solicitante:

NOVARTIS AG [CH]
UNIV PENNSYLVANIA [US]

WO_2018201056_A1

Resumen de: US2020055948A1

The invention relates to the treatment of diseases associated with expression of BCMA, in particular myelomas. The invention relates to combination therapies of a BCMA CAR-expressing cell and a gamma secretase inhibitor.

traducir

SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS)

NºPublicación: US2020055916A1 20/02/2020

Solicitante:

H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC [US]

JP_2020011979_A

Resumen de: US2020055916A1

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

traducir

USE OF ANTI-PL2L60 PROTEIN ANTIBODY IN PREPARATION OF ANTI-TUMOR MEDICINE AND METHOD FOR TREATING TUMOR

NºPublicación: US2020055950A1 20/02/2020

Solicitante:

SHANGHAI YIFANKE BIOTECHNOLOGY CO LTD [CN]

JP_2020500153_A

Resumen de: US2020055950A1

An is provided for inhibiting the dissimilar expression of a PIWIL2 gene and a protein antibody against the dissimilar expression of the PIWIL2 gene in preparation of an anti-tumor drug. It has been experimentally proved that, treating human or mouse tumor cells with KAO3 upon inoculation can effectively inhibit the tumorigenesis in a mouse. Furthermore, injecting KAO3 into established lymphoma, breast cancer, lung cancer and cervical cancer can significantly inhibit tumor growth and prolong the survival of a tumor-bearing mouse. The inhibitory effect of KAO3 is associated with KAO3-specific antigens expressed on the surface of a tumor cell. KAO3 induces apoptosis of the tumor cell by blocking the cell cycle in a G2/M phase, inhibiting DNA synthesis and activating a complement. Therefore, the anti-PL2L60 mAb (KAO3) is a potential therapeutic candidate drug for treating a cancer.

traducir

NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF

NºPublicación: US2020055918A1 20/02/2020

Solicitante:

UNIV MONTREAL [CA]

CA_3054089_A1

Resumen de: US2020055918A1

Minor histocompatibility antigens (MiHAs) binding to certain human leukocyte antigen (HLA) alleles are described. These MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these MiHAs are also described. The present application also discloses the use of these MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

traducir

Compounds, compositionals, and methods for treating T-cell acute lymphoblastic leukemia

NºPublicación: AU2018309739A1 20/02/2020

Solicitante:

THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK [US]

WO_2019028055_PA

Resumen de: AU2018309739A1

In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and δ, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.

traducir

CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3

NºPublicación: WO2020035676A1 20/02/2020

Solicitante:

AUTOLUS LTD [GB]

Resumen de: WO2020035676A1

The present disclosure provides a cell comprising: an anti-CD33 chimeric antigen receptor (CAR); an anti-CLL1 CAR; and an anti- CD123 and/or anti- CAR FLT3 CAR. The cell can be used in the treatment of a disease such as acute myeloid leukemia (AM L).

traducir

1-METHYL-4-(4-PHENYLPHENYL)SULFONYLMETHYLCYCLOHEXYANOL AND 1-METHYL-4-4-(2-PYRIDYL)PHENYLSULFONYLMETHYLCYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE

NºPublicación: WO2020035560A1 20/02/2020

Solicitante:

MODERN BIOSCIENCES LTD [GB]

Resumen de: WO2020035560A1

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

traducir

TREATMENT AND DIAGNOSIS OF MELANOMA

NºPublicación: AU2020200715A1 20/02/2020

Solicitante:

UNIV ROCKEFELLER

JP_2019151646_A

Resumen de: AU2020200715A1

A method of treating a drug resistant ovarian cancer, breast cancer, lung cancer, non-small cell lung cancer, glioblastoma, melanoma, bladder cancer, head and neck cancer, renal cell cancer, colorectal cancer, lymphoma, leukemia, multiple myeloma, or hepatocellular carcinoma, includes administering an effective amount of LXRP agonist, wherein the LXRP agonist is compound 2 or compound 25, or a pharmaceutically acceptable salt thereon, the compound 2 and compound 25 being 24-Jan-20

traducir

TREATMENT OF B CELL MALIGNANCIES

NºPublicación: WO2020036999A1 20/02/2020

Solicitante:

MEI PHARMA INC [US]

Resumen de: WO2020036999A1

Provided herein are methods of treating cancer using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the cancer is follicular lymphoma (FL). In certain embodiments, the PI3K inhibitor is administered on a continuous dosing schedule (CS). In other embodiments, the PI3K inhibitor is administered on an intermittent dosing schedule (IS).

traducir

TREATMENT OF RELAPSED FOLLICULAR LYMPHOMA

NºPublicación: WO2020036997A1 20/02/2020

Solicitante:

MEI PHARMA INC [US]

Resumen de: WO2020036997A1

Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the methods comprise treating FL in subjects having disease progression within 24 months of initiating first-line or subsequent immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor.

traducir

GENE SIGNATURE TO PREDICT CHEMOTHERAPY RESPONSE IN SUBJECTS WITH LYMPHOMA

NºPublicación: CA3014222A1 14/02/2020

Solicitante:

UNIV OF GUELPH [CA]

Resumen de: CA3014222A1

The present disclosure provides methods of detecting or screening for whether a subject with lymphoma will respond to CHOP therapy.

traducir

PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS

NºPublicación: WO2020033317A1 13/02/2020

Solicitante:

SOUTHERN RES INSTITUTE [US]
UAB RESEARCH FOUNDATION [US]

Resumen de: WO2020033317A1

The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

COMPOUNDS TARGETING HSP110 PROTEIN FOR CANCER TREATMENT

NºPublicación: WO2020030589A1 13/02/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV DE CAEN NORMANDIE [FR]
UNIV DE BOURGOGNE [FR]

Resumen de: WO2020030589A1

HSP110 is involved in multiple tumorigenic processes, but no inhibitor was known to date. The inventors have identified for the first time HSP110 inhibitors. These inhibitors bind directly to the nucleotide binding domain of HSP110 and then blocks the phosphorylation of STAT3, cancer cell growth or MyD88 stability. The present invention relates to a compound of general formula (I) for use in the treatment of a HSP 110-associated cancer, for example colorectal cancer and lymphoma. Especially the inventors tested the compound on two different colorectal mice models, a syngeneic model for which mouse colon cancer CT-26 cells were injected into Balb/c mice and a NOD/ SCID model in which mice were implanted with human colorectal cancer HCT116 cells. In those animals bearing a tumor, the compound induced tumor regression that was associated with the inhibition of other HSP110 reported tumorigenic functions (resistance to apoptosis, induction of pro-tumor macrophages). Further, the inventors also tested the compound on large B cell lymphoma cell lines (DLBCL). Specifically, the compound is able to alter the interaction between HSP110 and MyD88, which induces a degradation of the oncogene MyD88. Additionally, is has been showed that the compound act synergistically with other anticancer agents, including with tyrosine kinase inhibitors like Ibrutinib.

traducir

HETEROCYCLIC COMPOUNDS AND THEIR USES

NºPublicación: US2020048265A1 13/02/2020

Solicitante:

AMGEN INC [US]

NZ_579834_A

Resumen de: US2020048265A1

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

traducir

PRODRUG OF AN ICE INHIBITOR

NºPublicación: US2020048306A1 13/02/2020

Solicitante:

VERTEX PHARMA [US]

JP_2011236235_PA

Resumen de: US2020048306A1

Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

traducir

QUINOLINE DERIVATIVE FOR TREATING EXTRANODAL NK/T CELL LYMPHOMA

Nº publicación: WO2020029918A1 13/02/2020

Solicitante:

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD [CN]

Resumen de: WO2020029918A1

Provided is a quinoline derivative for treating extranodal NK/T cell lymphoma. The provided compound I or a pharmaceutically acceptable salt thereof can be used for treating extranodal NK/T cell lymphoma patients resistant to asparagine, especially recurrent or refractory extranodal NK/T cell lymphoma patients resistant to asparagine, with results of efficacy evaluation showing relieved symptoms and prolonged survival in the patients.

traducir

Página1 de 4 nextPage por página

punteroimgVolver